Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$4.15 - $6.24 $62,250 - $93,600
-15,000 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$4.54 - $7.17 $111,343 - $175,844
-24,525 Reduced 62.05%
15,000 $70,000
Q2 2021

Aug 16, 2021

SELL
$4.8 - $7.25 $98,232 - $148,371
-20,465 Reduced 34.11%
39,525 $279,000
Q1 2021

May 17, 2021

SELL
$4.57 - $7.18 $32,492 - $51,049
-7,110 Reduced 10.6%
59,990 $355,000
Q4 2020

Feb 16, 2021

BUY
$3.56 - $5.09 $181,314 - $259,238
50,931 Added 314.99%
67,100 $309,000
Q3 2020

Nov 16, 2020

BUY
$3.85 - $28.47 $62,250 - $460,331
16,169 New
16,169 $63,000

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.